Heart new drug trial fails! Novo Nordisk A/S Sponsored ADR Class B (NVO.US) stock price plunges before the market opens, intensifying the cloud of "weight loss drug dependence."

Danish pharmaceutical giant Novo Nordisk A/S Sponsored ADR Class B (NVO.US) faced a significant setback in research and development as the company announced on Friday that its much-anticipated heart drug ziltivekimab failed to meet its primary endpoint in a large Phase 3 clinical trial, causing its stock price to plunge more than 10% at one point during trading. The trial, named "Zeus," aimed to evaluate whether the monthly injection of the IL-6 inhibitor ziltivekimab, in addition to standard treatment, could further reduce the risk of major adverse cardiovascular events (MACE) in a specific patient population compared to a placebo. MACE is defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke, with Jefferies Financial Group Inc. estimating the market size to be over $10 billion annually. The trial enrolled over 6,300 patients suffering from atherosclerotic cardiovascular disease, chronic kidney disease, and elevated levels of inflammation. Results showed that although the drug effectively reduced the target protein in the body, indicating biological activity, this effect did not a statistically significant reduction in MACE risk. In terms of safety, the overall incidence of adverse events was similar between the two groups, but the ziltivekimab group experienced a higher rate of serious infections, with no difference in overall mortality. This outcome has left the market greatly disappointed. Analysts had previously widely expected the drug to at least demonstrate some efficacy. Jefferies Financial Group Inc. pointed out before the results were released that the study needed to see at least a 20% risk reduction to support widespread use, while BMO Capital Markets suggested that a 15% risk reduction accompanied by clean safety data could also be seen as a positive sign. Analysts from Goldman Sachs Group, Inc. indicated before the results were announced that had the trial succeeded, ziltivekimab could have become central to Novo Nordisk A/S Sponsored ADR Class Bs cardiovascular franchise, reducing the company's heavy reliance on Ozempic and Wegovy. In response to this blow, Novo Nordisk A/S Sponsored ADR Class B's stock price in Copenhagen sharply fell by 10.5%, marking the largest intraday drop since February of this year; its American Depository Receipts (ADR) also dropped over 8% in pre-market trading. As of Thursdays close, the company's ADR still retained a 5% gain for the year, although its Danish-listed stock had previously fallen by 7%. Novo Nordisk A/S Sponsored ADR Class B Chief Scientific Officer Martin Holst Lange stated, "Although ziltivekimab did not achieve the MACE benefits we hoped for, this does not change our strategic commitment to cardiovascular disease." The company has made it clear that it will continue to advance two other heart outcome trials for patients with heart failure and those post-acute myocardial infarction, with results expected in the first half of next year. Currently, competitors such as Novartis AG Sponsored ADR (NVS.US) and Eli Lilly (LLY.US) are also developing compounds targeting the same pathway. The failure to meet the primary endpoint is undoubtedly another blow for this Danish pharmaceutical company. The company is striving to restore investor confidence in its R&D pipeline and execution capabilities, especially in the challenging U.S. market.